Dr. Pius S. Fasinu

Assistant Professor
Pharmaceutical Sciences
College of Pharmacy & Health Sciences
Office Address:
Maddox Hall
Mailing Address:
205 Day Dorm Rd., Science Bldg. Rm 105A
Buies Creek, NC 27506


Dr. Fasinu’s research interests focus on drug metabolism and pharmacokinetics (DMPK) as applicable in clinical pharmacology and drug development. He utilizes liver-based drug biotransformation to elucidate the metabolic pathways of new chemical entities (NCEs), evaluate drug-drug and herb-drug interactions. He is also actively involved in pharmacokinetics, PKPD modeling and phase I clinical trials.


  • PhD Pharmacology, Stellenbosch University, South Africa
  • MSc (Med) Pharmacy, University of the Witwatersrand, South Africa
  • B.Pharm, Olabisi Onabanjo University, Nigeria
  • RPh MS, NC


  • Certified Immunizing Pharmacist
  • Certificate in Drug Discovery / Clinical Development, NIBR, Basel, Switzerland


  • American Pharmacists Association (APhA)
  • American Association of Colleges of Pharmacy (AACP)
  • American Society for Clinical Pharmacology and Therapeutics (ASCPT)
  • American Society for Pharmacology & Experimental Therapeutics (ASPET)
  • Pharmacologists for Africa Initiative (PharfA)


  • Fasinu PS, Manda VK, Dale OR, Egiebor NO, Walker LA, Khan SI (2017). Modulation of Cytochrome P450, P-glycoprotein and Pregnane X Receptor by Selected Antimalarial Herbs—Implication for Herb-Drug Interaction. Molecules 22(12):2049.
  • Fasinu PS, Choonara YE, Kumar P, du Toit LC, Bijukumar D, Khan RA, Pillay V (2017). Enhancement of the oral bioavailability of felodipine employing 8-arm-poly (ethylene glycol): in vivo, in vitro and in silico evaluation. AAPS PharmSciTech. 18:617-28
  • Fasinu PS, Muhammad I, Walker LA (2016). Update on advances in plant-based antimalarial drug discovery; In: Antiprotozoal Drug Discovery: A Challenge that Remains, pp 106-155. Publisher: Bentham Science Publishers, Editor: Norma Rivera
  • Fasinu PS, Tekwani BL, Avula B, Chaurasiya ND, Nanayakkara D, Wang Y, Khan IA, Walker LA (2016). Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine. Malaria J. 15:466.
  • Fasinu PS (2013). Toxic effects of traditional therapies; In: Oxford AFEM Handbook of Acute and Emergency Care, Edition: 1, Publisher: Oxford University Press, Southern Africa, Editors: Lee A. Wallis, Teri A. Reynolds.
  • Fasinu PS, Phillips S, ElSohly MA, Walker LA. Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2016 Jul 1;36(7):781-96.
  • Fasinu PS, Avula B, Tekwani BL, Nanayakkara NP, Wang YH, Bandara Herath HM, McChesney JD, Reichard GA, Marcsisin SR, Elsohly MA, Khan SI, Khan IA, Walker LA. Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes. Malar J. 2016 Apr 19;15(1):224.
  • Fasinu PS, Gurley BJ, Walker LA (2016). Clinically relevant pharmacokinetic herb-drug interactions in antiretroviral therapy. Current drug metabolism. 2016 Jan 1;17(1):52-64.
  • Fasinu PS, Tekwani BL, Nanayakkara NPD, Avula B, Herath BHMT, Wang Y-H, Adelli VR, Elsohly MA, Khan SI, Khan IA, Pybus BS, Marcsisin SR, Reichard GA, McChesney JD, Walker LA. (2014). Enantioselective metabolism of primaquine by human CYP2D6. Malaria Journal 13(1): 507.
  • Fasinu PS, Bouic P, Rosenkranz B. (2014). The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction. African Journal of Traditional, Complementary and Alternative medicines (AJTCAM), 11(4), 54-61).
  • Fasinu PS, Orisakwe O. (2013). Heavy metal pollution in sub-Saharan Africa and possible implication in cancer epidemic. Asian Pac J Cancer Prev. 2013;14(6):3393-402.
  • Fasinu PS, Heike Gutmann, Hilmar Schiller, Patrick Bouic and Bernd Rosenkranz (2013). The potential of Hypoxis hemerocallidea for herb-drug interaction. Pharmaceutical Biology 51(12), 1499-1507.
  • Fasinu PS, Gutmann H, Schiller H, James AD, Bouic P, Rosenkranz B. (2013). The potential of Sutherlandia frutescens for herb-drug interaction. Drug Metabolism and Disposition; 2013 Feb;41(2):488-97. doi: 10.1124/dmd.112.049593.
  • Fasinu PS, Choonara YE, du Toit LC, Kumar P, Ndesendo VMK, Khan RA, Pillay V. (2013). Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability: An in vitro and in silico comparative analysis. Journal of Pharmaceutical Sciences; 102(2):541-55.
  • Fasinu PS and Rosenkranz B. (2013). Drug-drug interactions in ageing HIV-infected individuals. African Journal of Pharmacy and Pharmacology; 6(38):2710-2723.
  • Fasinu PS, Bouic PJ, Rosenkranz B. (2013). An overview of the Evidence and mechanisms of herb–drug interactions. Front.Pharmacol. 3:69. doi:10.3389/fphar.2012.00069.
  • Fasinu PS, Bouic PJ, Rosenkranz B. (2012). Liver-based in vitro technologies for drug biotransformation studies – a review. Current Drug Metabolism; 13:215-224.
  • Fasinu PS, Pillay V, Ndesendo V, du Toit L, Choonara Y. (2011). Diverse approaches for the enhancement of oral drug bioavailability. Biopharmaceutics and Drug Disposition; 32:185-209.